The Quality of Life (QoL) surveys based on Global Health Status sub-score of EORTC QLQ-C30 were filled out by SARAH participants at baseline and at three-month intervals after their initial treatment.
The results underscored the benefit of SIR-Spheres® Y-90 resin microspheres on patients’ quality of life. In the Intention-To-Treat (ITT) population, the QoL was significantly better for patients who received SIRT compared to those who received sorafenib.
The results of the HCC-specific QLQ-HCC 18 questionnaire will be published separately.
Reprinted from The Lancet Oncology, Vol. 18, Vilgrain V, Pereira H, Assenat E et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial, Pages 1624-1636., Copyright (2017), with permission from Elsevier.
Vilgrain V et al. Lancet Oncol 2017; 18: 1624–36.